((自动化翻译由路透提供，请见免责声明 ))
9月30日 - ** Prime Medicine 股价在盘前大幅上涨14.7%至3.93美元
** 该公司称， (link)，它与百时美施贵宝 签署了一项研究合作与许可协议，该制药商将向PRME的股权投资5500万美元。
** PRME 表示，它还将获得 5,500 万美元的预付款，一旦完成某些销售和开发里程碑，预付款可能超过 35 亿美元。
** 开发和商业化多种疗法的协议
** 合作将 PRME 的基因编辑能力与 BMY 在新型细胞疗法的开发和商业化方面的专长相结合--PRME 表示
** 截至上一交易日收盘，PRME 的股价年累计下跌约 61
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.